Home Technology R&D Therapeutic Area Company News Careers Contact Find us » Novel treatments to help patients with central nervous system disorders News 2016-09-20 - BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research Read more » 2016-08-24 - Update from the Annual General Meeting 2016 Read more » 2016-04-19 - US patent on Parkinson’s disease granted Read more » 2016-03-15 - Antibody-based PET imaging of amyloid beta protofibrils in the Alzheimer brain – New findings from Uppsala University in collaboration with BioArctic Read more » 2015-09-28 - Innovative Alzheimer therapy: A new license agreement between BioArctic and Eisai on back-up program to BAN2401 Read more » Technology Antibodies targeting toxic proteins R&D First drug candidate in development for Alzheimer’s disease Therapeutic Area CNS disorders BioArctic enters a strategically important collaboration: Aiming for a disease modifying treatment for Parkinson’s disease Gunilla Osswald, CEO: “Our new partner AbbVie has shown a strong commitment to Parkinson’s disease and I am proud that they have chosen to collaborate with BioArctic. I am looking forward to a successful partnership that hopefully will result in a new, innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease.” Read more » Home Legal notice Contact BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, SWEDEN, Phone: +46-(0)8-6956930, Fax: +46-(0)8-6956939

Home Technology R&D Therapeutic Area Company News Careers Contact Find us » ) BioArctic enters a strategically important collaboration Aiming for a disease modifying treatment for Parkinson’s disease At BioArctic, we believe that science can transform a chronic and progressive movement disorder like Parkinson’s disease. We also know that breakthrough science doesn’t happen in isolation. It happens through outstanding internal collaboration and successful external partnerships. Our new partner AbbVie has shown a strong commitment to Parkinson’s disease. And, I am proud that they have chosen to collaborate with us to develop and commercialize BioArctic’s portfolio of antibodies directed against alpha-synuclein for the treatment of Parkinson’s disease and other potential indications. Current treatments are symptomatic and do not halt or modify the disease progression. We at BioArctic are dedicated to our aspiration of bringing a disease modifying treatment to the patients. I am looking forward to a successful partnership that hopefully will result in a new, innovative disease modifying treatment becoming available to the large number of patients suffering from Parkinson’s disease. Gunilla Osswald, Ph.D. CEO, BioArctic AB HomeLegal noticeContact © BioArctic AB, 2003-2016, BioArctic AB, Warfvinges väg 35, SE-112 51 Stockholm, SWEDEN, Phone: +46-(0)8-6956930, Fax: +46-(0)8-6956939